

## Department of Medicine - Publications 2008 - JGH

### Agulnik, Jason

--Melosky B, **Agulnik J**, Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. *Curr. Oncology*. 15:279-85, 2008

### Alaoui-Jamali, Moulay

--Prakesch M, Bijian K, Campagna-Slater V, Quevillon S, Joseph R, Wei CQ, Sesmilo E, Reayi A, Poondra RR, Barnes ML, Leek DM, Xu B, Loughheed C, Schapira M, **Alaoui-Jamali M**, Arya P. Bioorg. Building skeletally diverse architectures on the Indoline Scaffold: the discovery of a chemical probe of focal adhesion kinase signaling networks, *Med Chem*, 16:21:9596-602, 2008

--Behmoaram E, Bijian K, Jie S, Xu Y, Darnel A, Bismar TA, **Alaoui-Jamali MA**. Focal adhesion kinase-related proline-rich tyrosine kinase 2 and focal adhesion kinase are co-overexpressed in early-stage and invasive ErbB-2-positive breast cancer and cooperate for breast cancer cell tumorigenesis and invasiveness. *Am J Pathol*, 173:5:1540-50, 2008

--Behmoaram E, Bijian K, Bismar TA, **Alaoui-Jamali MA**. Early stage cancer cell invasion: signaling, biomarkers and therapeutic targeting. *Front Biosci*, 1:13:6314-25, 2008

### Assouline, Sarit

--Garcia-Manero G, **Assouline S**, Cortes J, Estrov Z, Kantarjian H, Yang H, Newsome WM, Miller WH Jr, Rousseau C, Kalita A, Bonfils C, Dubay M, Patterson TA, Li Z, Besterman JM, Reid G, Laille E, Martell RE, Minden M. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia. *Blood*, 112:4:981-9, 2008. Epub 2008 May 21.

--Franceschino A, Tornaghi L, Benemacher V, **Assouline S**, Gambacorti-Passerini C. Alterations in creatine kinase, phosphate and lipid values in patients with chronic myeloid leukemia during treatment with imatinib. *Haematologica*, 93:2:317-8, 2008

--Opatrny L, Dell'Aniello S, **Assouline S**, Suissa S. Hormone replacement therapy use and variations in the risk of breast cancer. *BJOG*, 115:2:169-75, 2008

### Autexier, Chantal

--Marie-Egyptienne DT, Brault ME, Zhu S and Autexier C. Telomerase inhibition in a mouse cell line with long telomeres leads to rapid telomerase reactivation. *Exp. Cell Res.* 314:668-675, 2008

--Kieltyka R, Englebienne P, Fakhoury J, Autexier C, Moitessier N, and Sleiman H. A platinum supramolecular square as an effective G-Quadruplex binder and telomerase inhibitor. *J. Am. Chem. Soc.* 130:10040-10041, 2008

--Shawi M and Autexier C. Telomerase, senescence and aging. *Mechanisms of Ageing and Development*, 129:3-10, 2008

--Autexier C. POT of gold: modeling dyskeratosis congenita in the mouse. *Genes & Development*, 22:1731-1736, 2008

### **Baron, Murray**

--**Baron M**, Schieir O, Hudson M, Steele R, Kolahi S, Berkson L, Couture F, Fitzcharles MA, Gagne M, Garfield B, Gutkowski A, Kang H, Kapusta M, Ligier S, Mathieu JP, Menard H, Starr M, Stein M, Zummer M. The clinimetric properties of the world health organization disability assessment schedule II in early inflammatory arthritis. *Arthritis Rheum*, 59:382-9, 2008

--**Baron M**, Sutton E, Hudson M, Thombs B, Markland J, Pope J, Robinson D, Jones N, Docherty P, Abu-Hakima M, LeClercq S, Smith D, Mathieu JP. The relationship of dyspnoea to function and quality of life in systemic sclerosis. *Ann Rheum Dis*, 67:644-50, 2008

--Dobkin PL, Filipski M, Looper K, Schieir O, **Baron M**. Identifying Target Areas of Treatment for Depressed Early Inflammatory Arthritis Patients. *Psychother Psychosom*, 77:298-305, 2008

--Santiago M, **Baron M**, Miyachi K, Fritzler MJ, Abu-Hakima M, Leclercq S, Bell M, Hudson M, Mathieu JP, Taillefer S, Jones N, Docherty P, Khraishi M, Markland J, Pope J, Robinson D, Smith D, Sutton E. A comparison of the frequency of antibodies to cyclic citrullinated peptides using a third generation anti-CCP assay (CCP3) in systemic sclerosis, primary biliary cirrhosis and rheumatoid arthritis. *Clin Rheumatol*, 27:77-83, 2008

--Villela R, Yuen SY, Pope JE, **Baron M**. Assessment of unmet needs and the lack of generalizability in the design of randomized controlled trials for scleroderma treatment. *Arthritis Rheum*, 59:706-13, 2008

--Dobkin P, Ionescu-Ittu R, Abrahamowicz M, **Baron M**, Bernatsky S, Sita A. Predictors of Adherence to an Integrated Multimodal Program for Fibromyalgia. *J Rheumatol*, in press, 2008

### **Bergman, Howard**

--Lafortune L, Béland F, **Bergman H**. Fragilité, incapacité et dépendance des personnes âgées: comment compléter l'architecture du système de santé. Dans: Le Privé dans la santé. Les discours et les faits. Les Presses de l'Université de Montréal, Chapitre 16:367-386, 2008

--Abellan Van Kan G, Rolland Y, **Bergman H**, Morley JE, Kritchevsky SB, Vellas B (on behalf of the Geriatric Advisory Panel). Frailty Assessment of Older People in Clinical Practice Expert Opinion of a Geriatric Advisory Panel. *Journal of Nutrition, Health & Aging*, 12:29-37, 2008

--Béland F, **Bergman H**, Lebel P et al. Des services intégrés pour les personnes âgées fragiles (SIPA): expérimentation d'un modèle pour le Canada. *Gérontologie et société*, 124:49-83, 2008

--Wong CH, Wong SF, Yusoff AM, Karunanathan S, **Bergman H**. The Effect of a Later-life Health Promotion on Functional Performance and Body Composition. *Aging Clinical and Experimental Research*, 20:454-460, 2008

--**Bergman H**, Hogan D, Karunanathan S. Frailty: A clinically relevant concept? Canadian Journal of Geriatrics, 11:124-128, 2008

--Houde M, **Bergman H**, Whitehead V, **Chertkow H**. A Predictive Depression Pattern in Mild Cognitive Impairment. International Journal of Geriatric Psychiatry, 23:1028-33, 2008

### **Berkson, Laeora**

--Schieir O, Thombs B, **Berkson L**, Couture F, Fitzcharles M, Gagné M, Garfield B, Gutkowski A, Hudson M, Kang H, Kapusta M, Ligier S, Mathieu J-P, Ménard H, Starr M, Stein M, Zummer M, Baron M. Symptoms of depression predict trajectory of pain among patients with early inflammatory arthritis: A path analysis approach to assessing pain. J Rheumatology, December 15, 2008 [Epub ahead of print].

### **Blank, Volker**

--Li W, Yu S, Liu, T, Kim J-H, **Blank V**, Li H & Kong A-N . Heterodimerization with small Maf protein enhances nuclear retention of Nrf2 via masking the NESzip motif. Biochimica Biophysica Acta, 1783:1847-56, 2008

--**Blank V**, Hirsch E, Challis JRG, Romeo R & Lye SJ. Cytokine signaling, inflammation, innate immunity and preterm labour. Placenta, S102-104, 2008

--**Blank V**. Small Maf proteins in mammalian gene control: mere dimerization partners or dynamic transcriptional regulators? Journal of Molecular Biology, 376: 913-25, 2008

### **Blostein, Mark**

--**Blostein M**, Cuerquis J, Landry S, **Galipeau J**. The carboxylation efficiency of the vitamin K dependent clotting factors: Studies with factor IX. Haemophilia, 14:5:1063-8, 2008. Epub Aug 1, 2008.

--Coutu DL, Wu JW, Monnette A, Rivard GE, **Blostein MB**, **Galipeau J**. Periostin: A member of a novel family of vitamin-K dependent proteins is expressed by mesenchymal stromal cells. J Biol Chem, 283:26:17991-18001, 2008. Epub Apr 30, 2008.

--Ganopolsky JG, Charbonneau S, Peng HT, Shek PN, **Blostein MD**. Characterization of an ideal amphipathic peptide as a procoagulant agent, Biochemical Journal, 412: 545-51 2008.

--Ganopolsky JG, Abid R, Aird W, **Blostein MD**. Gas6-induced signaling in human endothelial cells is mediated by FOXO1a. J. Thromb & Hemostasis, 6:1804–1811, 2008

--Peng HT, **Blostein MD**, Shek PN. Experimental optimization of an in-situ-forming hydrogel for hemorrhage control. Journal of Biomaterials Research, Part B: Applied Biomaterials, Epub Sep 2008

--Rajotte I, Hasanbasic I, **Blostein MD**. Gas6-mediated signaling is dependent on the engagement of its gamma-carboxyglutamic acid domain with phosphatidylserine. *Biochemical and Biophysical Research Communications*, 376:70–73, 2008

### **Cen, Shan**

--Zhang L, Li X, Ma J, Yu L, Jiang J, and **Cen S\***. The incorporation of APOBEC3 proteins into Murine leukemia viruses. *Virology*, 15:378:69-78, 2008

--Saadatmand J, Guo F, **Cen S**, Niu M, Kleiman L. Interactions of reverse transcriptase sequences in Pol with Gag and LysRS in the HIV-1 tRNA<sup>Lys3</sup> packaging/annealing complex. *Virology*, 380:109-17, 2008

### **Chalifour, Lorraine E.**

--Kucic T, Copland IB, Cuerquis J, Coutu DL, **Chalifour LE**, Gagnon RF, Galipeau J. Mesenchymal stromal cells genetically engineered to overexpress Insulin-like Growth Factor-1 provide paracrine support for cell-based erythropoietin therapy of chronic renal failure-induced anemia. *Am J Physiol Renal Physiol*. 295:2:F488-96, 2008. Epub Jun 4, 2008.

--Mwale F, Marguier, Ouellet J, Antoniou J, and **LE Chalifour**. Effect of dexrazoxane and amifostine on the vertebral bone quality of doxorubicin treated male rats. *The Open Orthopaedics Journal*, 2:115-120, 2008

### **Chertkow, Howard**

--Babins L, Slater M-E, Whitehead V, **Chertkow H**. Can an 18-point clock drawing scoring system predict dementia in elderly individuals with Mild Cognitive Impairment? *Journal of Clinical and Experimental Neuropsychology*, 30:173-186, 2008

--**Chertkow H**. Diagnosis and treatment of dementia: Introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia. *Canadian Medical Association Journal (CMAJ)*, 178:316-321, 2008

--Taler V, Baum S, **Chertkow H**, Saumier D. Comprehension of grammatical and emotional prosody is impaired in Alzheimer's disease. *Neuropsychology*, 22:188-195, 2008

--Djordjevic J, Jones-Gotman M, De Sousa K, **Chertkow H**. Olfaction in patients with mild cognitive impairment and Alzheimer's disease. *Neurobiology of Aging*, 29:693-706, 2008

--Feldman H.H, Jacova C, Robillard A, Garcia A, Chow T, Borrie B, Schipper H.M, Blair M, Kertesz A, **Chertkow H**. Diagnosis and treatment of dementia: 2. Diagnosis. *Canadian Medical Association Journal (CMAJ)*, 178:825-836, 2008

--Fellows L, **Chertkow H**, **Bergman H**, Wolfson C. Can clinical data predict progression to dementia in elderly patients with amnesic Mild Cognitive Impairment? *Canadian Journal of Neurological Sciences*, 35:314-322, 2008

- Whatmough C, Nikelski, J, Monchi O, **Chertkow H**. Increased neural efficiency in the temporal association cortex as the result of semantic task repetition. *Human Brain Mapping*, 29 :922-930, 2008
- Belleville S, Bherer L, Lepage E, **Chertkow H**, Gauthier S. Task switching capacities in persons with Alzheimer's disease and mild cognitive impairment. *Neuropsychologia*, 46:2225-2233, 2008
- Hogan DB, Bailey P, Black S, Carswell A, **Chertkow H**, Clarke B, et al. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. *Canadian Medical Association Journal (CMAJ)*, 179:787-793, 2008
- Hogan DB, Bailey P, Black S, Carswell A, **Chertkow H**, Clarke B, et al. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. *Canadian Medical Association Journal (CMAJ)*, 179:1019-1026, 2008
- Chertkow H**, Massoud F, Nasreddine Z, Belleville S, Joanne Y, Bocti C, Drolet V, Kirk J, Freedman M, **Bergman H**. Diagnosis and Treatment of Dementia: Mild Cognitive Impairment and Cognitive Impairment without Dementia. *CMAJ*, 178:1273-1285, 2008
- Su H, Gornitsky M, Geng G, Velly AM, **Chertkow H**, **Schipper HM**. Diurnal variations in salivary protein carbonyl levels in normal and cognitively-impaired human subjects. *AGE*, 30:1-9, 2008
- Kearney P, Currier N.L, Chelsky D, Desjardins C, Hugo P, Hunter J, Paramithiotis E, Riviere M, Maes O, **Chertkow H**, **Schipper H.M**. Global Proteomics: Pharmacodynamic decision making via geometric interpretations of proteomic analyses. *Journal of Proteomics & Bioinformatics*, 1:315-328, 2008
- Chertkow H**, Whatmough C, Saumier D, Duong A. Cognitive neuroscience studies of semantic memory loss in Alzheimer's disease. In W Sossin, J-C Lacaille, V. F. Castellucci, S Belleville (Eds), Progress in Brain Research, Essence of Memory, Chapter 25:393-407, 2008

### **Clarfield, Avram M**

- Shemesh AA, Rasooly I, Horowitz P, Lemberger J, Ben-Moshe Y, Kachal J, Danziger J, **Clarfield AM**, Rosenberg E. Health behaviors and their determinants in multiethnic, active Israeli seniors. *Arch Gerontol Geriatr*, 47:63-77, 2008
- Brodsky J, **Clarfield AM**. Long Term Care in Health Services. In: Kris Heggenhougen and Stella Quah (eds): International Encyclopedia of Public Health, vol.4, Academic Press: San F Diego:127-132, 2008

### **Cohen, Albert**

- Shugart YY, Silverberg MS, Duerr RH, Taylor KD, Wang MH, Zarfes K, Schumm LP, Bromfield G, Steinhart AH, Griffiths AM, KANE SV, Barmada MM, Rotter JI, Mei L, Bernstein CN, Bayless TM, Langelier D, **Cohen A**, Bitton A, Rioux JD, Cho JH, Brant SR. An SNP linkage scan

identifies significant Crohn's disease loci on chromosomes 13q13.3 and in Jewish families on 1p35.2 and 3q29. *Genes Immun*, 9:161-7, 2008

### **Cohen, S Robin**

--Stajduhar KI, Allan DE, S. **Cohen SR**, Heyland DK. Preferences for location of death of seriously ill hospitalized patients: Perspectives from Canadian patients and their family caregivers. *Palliative Medicine*, 22:85-88, 2008

--Macdonald ME, Liben S, Carnevale FA, **Cohen SR**. Signs of life and signs of death: Brain Death and other mixed messages at the end of life. *Journal of Child Health Care*, 12: 93-106, 2008

--Henry M, Nuoxin Huang L, Ferland M.K, Mitchell J, **Cohen SR**. Continued study of the psychometric properties of the McGill Quality of Life Questionnaire (MQOL). *Palliative Medicine*, 22:718-723, 2008

--Stajduhar KS and **Cohen SR**. Family carers in the home. In: Family Carers in Palliative Care. Eds. P. Hudson and S Payne. Oxford University Press, England, 2008

### **Dascal, Andre**

--Brenner BG, Roger M, Moisi DD, Oliveira M, Hardy I, Turgel R, Charest H, Routy JP, Wainberg MA; Montreal PHI Cohort and HIV Prevention Study Groups (including **Dascal A**). Transmission networks of drug resistance acquired in primary/early stage HIV infection. *AIDS*, 22:18:2509-15, 2008

--Dial S, Kezouh A, **Dascal A**, Barkun A, Suissa S, Patterns of antibiotic use and risk of hospital admission because of *Clostridium difficile* infection among elderly people in Quebec. *CMAJ*. 179:767-72, 2008

--Quan Y, Brenner BG, **Dascal A**, Wainberg MA. Highly diversified multiply drug-resistant HIV-1 quasispecies in PBMCs: a case report. *Retrovirology*, 305:43, 2008

### **Eintracht, Shaun**

--Gan R, **Eintracht S**, Hoffer LJ. Vitamin C deficiency in a university teaching hospital. *J Am Coll Nutr*. 27:428-33, 2008

### **Eisenberg, Mark**

--Pilote L, Beck CA, **Eisenberg MJ**, Humphries K, Joseph L, Penrod JR, Tu JV. Comparing invasive and noninvasive management strategies for acute myocardial infarction using administrative databases. *Am Heart J*, 155:42-8, 2008

--Afilalo J, Duque G, Steele R, Jukema JW, de Craen AJ, **Eisenberg MJ**. Statins for secondary prevention in elderly patients: A hierarchical Bayesian meta-analysis. *J Am Coll Cardiol*, 51:37-45, 2008

--Rinfret S, Behloul H, **Eisenberg MJ**, Humphries K, Tu JV, Pilote L. Class effects of statins in elderly patients with congestive heart failure: A population-based analysis. *Am Heart J*, 155:316-23, 2008

--Filion KB, Pilote L, Rahme E, **Eisenberg MJ**. Use of perioperative cardiac medical therapy among patients undergoing coronary artery bypass surgery. *J Cardiac Surg*, 23:209-15, 2008

--Shrier I, Boivin JF, Platt RW, Steele RJ, Brophy J, Carnevale F, **Eisenberg MJ**, Furlan A, Kakuma R, Macdonald MR, Pilote L, Rossignol M. The interpretation of meta-analyses: An objective or subjective process? *BMC Med Inform Decis Mak*, 8:19, 2008

--Pilote L, Abrahamowicz M, **Eisenberg MJ**, Humphries K, Behloul H, Tu JV. Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure. *CMAJ*, 18: 1303-11, 2008

--**Eisenberg MJ**. Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, Gervais A, O'Loughlin J, Paradis G, Rinfret S, Pilote L. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. *CMAJ*, 179: 135-44, 2008

--Sharma K, **Eisenberg MJ**. Putting the benefits of percutaneous coronary revascularization into perspective: From trials to guidelines. *Curr Cardiol Reports*, 10:393-401, 2008

Mottillo S, Filion KB, Belisle P, Joseph L, Gervais A, O'Loughlin J, Paradis G, Pihl R, Pilote L, Rinfret S, Tremblay M, **Eisenberg MJ**. Behavioral interventions for smoking cessation: A meta-analysis of randomized controlled trials. *Eur Heart J* 2008 (Epub)

## **Ernst, Pierre**

--**Ernst P**, Franssen E, Chan CKN, Okell M, O'Byrne P, Bai T. Predictors of a more favourable response to combined therapy with salmeterol and fluticasone as initial maintenance therapy in asthma. *Resp Med*, 102:77-81, 2008

--Langsetmo L, Platt RW, **Ernst P**, Bourbeau J. Underreporting exacerbation of chronic obstructive pulmonary disease in a longitudinal cohort. *Am J Respir Crit Care Med*. 177:396-401, 2008

--Shannon J, **Ernst P**, Yamauchi Y, Olivenstein R, Lemiere C, Foley S, Cicora L, Ludwig M, Hamid Q, Martin JG. Differences in airway cytokine profile in severe asthma compared to moderate asthma. *Chest*, 133:420-6, 2008

--Suissa S, **Ernst P**, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of chronic obstructive pulmonary disease. *Eur Respir J*, 31:927-933, 2008

--**Ernst P**, Suissa S. Pneumonia in elderly patients with chronic obstructive pulmonary disease. *Curr Infect Dis Rep*, 10:223-228, 2008

--Balter M, **Ernst P**, Watson W, Kim H, Cicutto L, Beauchesnes MF, Cave AJ, Kaplan A, Hogg D, McIvor A, Smiley T, Rouleau M, FitzGerald JM. Asthma worsening: approaches to prevention and management from asthma worsening working group. *Can Respir J*, 15:1B-19B, 2008

## **Galipeau, Jacques**

--Copland IB, Jolicoeur ME, Gillis MA, Cuerquis J, Eliopoulos N, Annabi B, Calderone A, Tanguay JF, Ducharme A, **Galipeau J**. Coupling erythropoietin secretion to mesenchymal stromal cells enhances their regenerative properties. *Cardiovasc Res*. 79:3:405-15, 2008. Epub Apr 8, 2008.

--Copland I, Sharma K, Lejeune L, Eliopoulos N Stewart D, Liu P, Lachapelle K, **Galipeau J**. CD34 Expression on Murine Marrow-derived Mesenchymal Stromal Cells: Impact on Neovascularization. *Experimental Hematology*. 36:93-103, 2008. Epub 2007 Nov 26.

--El-Ayoubi R, Eliopoulos N, DiRaddo R, **Galipeau J**, Yousefi A. Design and Fabrication of 3D Porous Scaffolds to Promote Cell-Based Gene Therapy. *Tissue Engineering Part A*, 1037-1048, 2008. Epub ahead of print Apr 9 2008

--Eliopoulos N, Francois M, Boivin m, Martineau D, **Galipeau J**. Neo-Organoid of Marrow Mesenchymal Stromal Cells Secreting Interleukin-12 for Breast Cancer Cellular Therapy. *Cancer Research*, 68:12:4810-8, 2008

--Fortier S, Touaibia M, Lord-Dufour S, **Galipeau J**, Roy R, Annabi B. Tetra and hexavalent mannosides inhibit the pro-apoptotic, anti-proliferative and cell surface clustering effects of concanavalin-A: Impact on MT1-MMP functions in marrow-derived mesenchymal stromal cells. *Glycobiology*. 18:195-204, 2008. Epub 2007 Dec 8.

--Penafuerte C, **Galipeau J**. TGF $\beta$  secreted by B16 melanoma antagonizes cancer gene immunotherapy bystander effect. *Cancer Immunol Immunother*. 57:1197-206, 2008. Epub Jan 24, 2008.

--Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, Forner K, Boivin MN, Doody K, Tremblay M, Annabi B, **Galipeau J**. Mesenchymal stromal cell derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. *Blood*, 112:13:4991-8, 2008. Epub 2008 Sep 23.

--Spaner DE, Foley R, **Galipeau J**, Bramso J. Obstacles to effective Toll-like receptor agonist therapy for hematological malignancies. *Oncogene*, 27:2:208-17, 2008

## **Greenaway, Christina**

--Menzies D, Farhat M, **Greenaway C**, Pai M. "Thinking in three dimensions: A web-based algorithm to aid the interpretation of the tuberculin skin test results". *The International J of Tuberculosis and Lung Disease*, 12:498-505, 2008

## **Hilzenrat, Nir**

--Turbide C, Soulellis CA, Deschenes M, **Hilzenrat N**. Does rapid decline in the haematological and biochemical parameters induced by interferon and ribavirin combination therapy for the



hepatitis C virus predict a sustained viral response? Canadian Journal of Gastroenterology, 22: 149-152, 2008

--Kirhstein B, **Hilzenrat N**, Yaari A, Souter KJ, Artru AA, Shapira Y, Sikuler E. Hemodynamic changes in visceral organs following closed head trauma in rats. Resuscitation, 77:127-131, 2008

--Soulellis C, **Hilzenrat N**, Levental M. Intramucosal oesophageal dissection leading to esophageal perforation: case report and review of the literature. Gastroenterology and hepatology, 4:362-365, 2008

--Neuman MG, Sha K, Esguerra R, Zakhari S, Winkler RE, **Hilzenrat N**, Wyse J, Cooper CL, Seth D, Gorrell MD, Haber PS, McCaughan GW, Leo MA, Lieber CS, Voiculescu M, Buzatu E, Ionescu C, Dudas J, Saile B, Ramadori G. Inflammation and repair in viral Hepatitis C. Digestive diseases and sciences, 53:1468-87, 2008

### **Hiscott, John**

--Oliere S, Arguello M, Mesplede T, Tumilasci V, Nakhaei P, Grandvaux N, Sonenberg N, Bell JC, and **Hiscott J**. VSV oncolysis of T lymphocytes requires cell cycle entry and translation initiation J. Virol. 82:5735-5749, 2008

--Tumilasci V, Oliere S, Nguyen T-L, Bell J, **Hiscott J**. Targeting the apoptotic pathway with Bcl-2 inhibitors sensitizes chronic lymphocytic leukemia to VSV-induced oncolysis. J. Virol. 82:8487-8499, 2008

--Nguyen L-A, Abdelbary H, Arguello M, Breitbach C, Leveille S, Yasmeeen A, Bismar T, Falls T, Werier J, **Hiscott J**, Bell JC. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis Proc. Natl. Acad. Sci. USA. 105: 14981-14986 (2008).

--**Hiscott J**, Paz S, Arguello M. Interferon regulatory factors and the atypical IKK-related kinases – TBK1 and IKKe: essential players in the innate immune response to RNA virus infection. In: Cellular signaling and innate immune responses to RNA virus infections. pp 51-74 Ed. Allan Brasier, Adolfo Garcia-Sastre, Stanley Lemon. ASM Publishers, 2008.

### **Hoffer, L. John**

--**Hoffer LJ**. Vitamin therapy in schizophrenia. Israel Journal of Psychiatry 45:3-10, 2008

--**Hoffer LJ**, Levine M, Assouline S, Melnychuk D, Paddayatty SJ, Rosadiuk K, Rousseau C, Robitaille L, Miller WH Jr. Phase I Clinical Trial of Intravenous Ascorbic Acid in Advanced Malignancy. Annals of Oncology 19:1969-1974, 2008

### **Hudson, Marie**

--Bernatsky S, **Hudson M**, Pope J, Vinet E, LeClercq S, Robinson D, Jones N, Markland J, Abu-Hakima M, Mathieu J-P, Docherty P, Khalidi N, Sutton E, Baron M, and the Canadian Scleroderma

Research Group. Assessment of Reproductive History in Systemic Sclerosis. *Arthritis Rheum*, 59:1661-4, 2008

--Bernatsky S, Panopolis P, **Hudson M**, Pope J, LeClercq S, Robinson D, Jones N, Markland J, Abu-Hakima M, Mathieu J-P, Docherty P, Khalidi N, Sutton E, Baron M, and the Canadian Scleroderma Research Group Demographic and Clinical Factors Associated with Physician Service Use in Systemic Sclerosis *J Rheumatology*, November 15, 2008 [Epub ahead of print]

-- **Hudson M**, Bernatsky S, Taillefer S, Fortin PR, Wither J, Canadian Scleroderma Research Group, Canadian Network for Improved Outcomes in Systemic Lupus Erythematosus, Baron M. Patients with Systemic Auto-Immune Diseases Could Not Distinguish True Co-morbidities from their Index Disease. *Journal of Clinical Epidemiology. J Clin Epidemiol*, 61:654-62, 2008

--**Hudson M**, Rojas-Villarraga A, Coral-Alvarado P, Lopez-Guzman S, Mantilla RD, Chalem P, Baron M, Anaya JM. Polyautoimmunity and familial autoimmunity in systemic sclerosis. *J Autoimmun*, 31:156-9, 2008

--**Hudson M**, Taillefer S, Steele R, Baron M. Quality of life in systemic sclerosis: psychometric properties of the World Health Organization Disability Assessment Schedule II. *Arthritis Rheum*, 59:279-84, 2008

--**Hudson M**, Thombs BD, Steele R, Watterson R, Taillefer S, Baron M and the Canadian Scleroderma Research group. Clinical Correlates of Quality of Life in Systemic Sclerosis Measured with the World Health Organization Disease Assessment Schedule II. *Arthritis Rheum*, 59:279-284, 2008

--Thombs BD, Fuss S, **Hudson M**, Schieir O, Taillefer SS, Fogel J, Ford DE, Baron M. High rates of depressive symptoms among patients with systemic sclerosis are not explained by differential reporting of somatic symptoms. *Arthritis Rheum*, 59:431-7, 2008

--Thombs BD, **Hudson M**, Schieir O, Taillefer SS, Baron M. Reliability and validity of the center for epidemiologic studies depression scale in patients with systemic sclerosis. *Arthritis Rheum*, 59:438-43, 2008

--Thombs BD, **Hudson M**, Taillefer SS, Baron M. Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. *Arthritis Rheum*, 59:504-9, 2008

--**Hudson M**, Suissa S. Perspective on the risks of infection and malignancy with rheumatoid arthritis therapy. *Future Rheumatology*, 3:445-449, 2008

--Thombs B, Bassel M, McGuire L, Smith MT, **Hudson M**, Haythornthwaite JA. A systematic comparison of fatigue levels in systemic sclerosis with general population, cancer and rheumatic disease samples. *Rheumatology*, 47:1559-63, 2008 Epub Aug 13, 2008

--Bernatsky S, Panopolis P, Clarke A, **Hudson M**, Pope J, LeClercq S, Markland J, Robinson D, Jones N, Docherty P, Abu-Hakima M, Mathieu J-P, St. Pierre Y, Smith C, Khalidi N, Sutton E, Baron M, and the Canadian Scleroderma Research Group The Cost of Systemic Sclerosis. *Arthritis Care Res*, in press, 2008

## **Joyal, Dominique**

-- **Joyal D**, Dieter RS. Vascular closure devices: have we caught the right FISH? *J Invasive Cardiol.* 2008 Apr;20(4): 157-8, **2008**

## **Kahn, Susan**

--Rey E, Garneau P, David M, Gauthier R, Leduc L, Michon N, Morin F, Demers C, **Kahn SR**, Magee LA, Rodger MA. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: A pilot randomized controlled trial. *J Thromb Haemost* , 7:58-64, 2008

--**Kahn SR**, Shrier I, Julian JA, Ducruet T, Arsenault L, Miron —J, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Lamping DL, Johri M and Ginsberg JS. Determinants and time course of the post-thrombotic syndrome after acute deep venous thrombosis. *Annals Intern Med*, 149:698-707, 2008

--**Kahn SR**, Shrier I, Kearon C. Physical activity in patients with deep venous thrombosis: A systematic review. *Thrombosis Research*, 122:763-773, 2008

--Kearon C, Julian JA, Kovacs MJ, Anderson DR, Wells P, Mackinnon B, Weitz JI, Crowther MA, Dolan S, Turpie AG, Geerts W, Solymoss S, van Nguyen P, Demers C, **Kahn SR**, Kassis J, Rodger M, Hambleton J, Gent M, Ginsberg JS. for the ELATE Investigators. Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: Results from a randomized trial. *Blood*, 112:4432-4436, 2008

--Rodger MA, **Kahn SR**, Wells PS, Anderson DA, Chagnon I, Le Gal G, Solymoss S, Crowther M, Perrier A, White R, Vickars L, Ramsay T, Betancourt M and Kovacs MJ. Identifying low risk unprovoked thromboembolism patients who can discontinue long term oral anticoagulants. *CMAJ*, 179:417-426, 2008

--Shbaklo H, **Kahn SR**. Long term prognosis after deep venous thrombosis. *Curr Opin Hematol*, 15:494–498, 2008

--Rodger MA, Paidas M, McLintock C, Middeldorp S, **Kahn SR**, Martinelli I, Hague W, Montella KR, Greer I. Inherited Thrombophilia and Pregnancy Complications Revisited. *Obstet Gynecol*, 112:320-324, 2008

--**Kahn SR**, Shbaklo H, Lamping DL, Holcroft CA, Shrier I, Miron M-J, Roussin A, Desmarais S, Joyal F, Kassis J, Solymoss S, Desjardins L, Johri M and Ginsberg JS. Determinants of health-related quality of life during the 2 years following deep vein thrombosis. *J Thromb Haemost*, 6:1105-1112, 2008

--Kearon C, **Kahn SR**, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: ACCP evidence-based clinical practice guidelines (8th edition). *Chest*, 133(Suppl.6):454S–545S, 2008

--Fox MA, **Kahn SR**. Post-thrombotic syndrome after vena cava filter placement: A systematic review. *J Vasc Interv Radiol*, 19:981-985, 2008

--Rodger MA, **Kahn SR**, LeGal G, Solymoss S, Chagnon L, Anderson DR, Wells PS and Kovacs J. Inter-observer reliability of measures to assess the post-thrombotic syndrome. *Thromb Haemost*, 100:164-166, 2008

--Rahme E, Dasgupta K, Burman M, Yin H, Bernatsky S, Berry G, Nedjar H, **Kahn SR**. Postdischarge thromboprophylaxis and mortality risk after hip- or knee- replacement surgery. *Can Med Assoc J*, 178:1545-1554, 2008

--O'Donnell MJ, McRae S, **Kahn SR**, Julian JA, Kearon C, Mackinnon B, Magier D, Strulovich C, Lyons T, Robinson S, Hirsh J, Ginsberg JS. Evaluation of a venous-return assist device to treat severe post-thrombotic syndrome (VENOPTS). A randomized controlled trial. *Thromb Haemost*, 99:623-629, 2008

### **Karaplis, Andrew**

--Gupta A, Välimäki VV, J Välimäki M, Löyttyniemi E, Richard M, L Bukka P, Goltzman D, **Karaplis AC**. Variable number of tandem repeats polymorphism in parathyroid hormone-related protein as predictor of peak bone mass in young healthy Finnish males. *Eur J Endocrinol* 158:755-764, 2008

--Cao G, Gu Z, Ren Y, Shu L, Tao C, **Karaplis A**, Goltzman D, Miao D. Parathyroid hormone contributes to regulating milk calcium content and modulates neonatal bone formation cooperatively with calcium. *Endocrinology* 150:561-569, 2009

--Bai X, Dinghong Q, Miao D, Goltzman D, **Karaplis AC**. Klotho ablation converts the biochemical and skeletal alterations in FGF23 (R176Q) transgenic mice to a Klotho-deficient phenotype. *Am J Physiol Endocrinol Metab* 296:E79-88, 2009

--Miao D, Su H, He B, Gao J, Xia Q, Zhu M, Gu Z, Goltzman D, **Karaplis AC**. Severe growth retardation and early lethality in mice lacking the nuclear localization sequence and C-terminus of PTH-related protein. *Proc Natl Acad Sci USA* 105:20309-20314. 2008

### **Kleiman, Lawrence**

--Wei M, Yang Y, Niu M, Desfosse L, Kennedy R, Musier-Forsyth K, and **Kleiman L**. Inability of HIV-1 produced in murine cells to selectively incorporate primer tRNA<sup>Lys3</sup>. *J. Virology*, 82:12049-12059, 2008

--Zhang Li, Li X, Niu M, Kleiman L and Cen S. Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. *Virology*, 370:113-121, 2008

### **Langleben, David**

--Cacoub P, Amoura Z, **Langleben D**. Treatment of pulmonary hypertension by endothelin receptor antagonists in 2008. *Rev Med Interne*, 29:283-289, 2008

--**Langleben D**, Orfanos SE, Giovinazzo M, Hirsch A, Baron M, Senecal JL, Armaganidis A, Catravas JD. Pulmonary capillary endothelial dysfunction: Severity in pulmonary arterial hypertension related to connective tissue disease versus idiopathic arterial hypertension. *Arthr Rheumatism*, 58:1156-1164, **2008**

--Orfanos SE, Hirsch AM, Giovinazzo M, Armaganidis A, Catravas JD, **Langleben D**. Pulmonary capillary endothelial metabolic function in chronic thromboembolic pulmonary hypertension. *J Thromb Haemost*, 6:1275-1280, 2008

### **Laughrea, Michael**

--Song R, Kafaie J, **Laughrea M**. Role of the 5' TAR Stem-Loop and the U5-AUG Duplex in Dimerization of HIV-1 Genomic RNA, *Biochemistry*, 47: 3283-3293, 2008

--Kafaie J, Song R, Abrahamyan L, Mouland AJ, **Laughrea M**. Mapping of nucleocapsid residues important for HIV-1 genomic RNA dimerization and packaging, *Virology*, 375:592-610, 2008

### **LeBlanc, Andrea**

--Klaiman G, Petzke T, Hammond J, **LeBlanc AC**. Targets of caspase-6 activity in human neurons and in Alzheimer disease. *Mol. Cell Proteomics*, 7:1541-1555, 2008

--Lin DTS, Jodoin J, Baril M, Goodyer CG, **LeBlanc AC**. Cytosolic prion protein is the predominant anti-Bax prion protein form: exclusion of transmembrane and secreted prion protein forms in the anti-Bax function. *BBA Mol. Cell Res.* 1783:10:2001-12, 2008

--**LeBlanc AC**. Introspective analysis of amyloid as the cause of Alzheimer disease: alternative model proposed. *Future Neurology*. 3:5:527-536, 2008

### **Lehoux, Stephanie**

--Billon A, **Lehoux S**, Lam Shang Leen L, Laurell H, Filipe C, Benouaich V, Brouchet L, Dessy C, Gourdy P, Gadeau AP, Tedgui A, Balligand JL, Arnal JF. The estrogen effects on endothelial repair and mitogen-activated protein kinase activation are abolished in endothelial nitric-oxide (NO) synthase knockout mice, but not by NO synthase inhibition by n-Nitro-l-Arginine Methyl Ester. *Am J Pathol.* 172:830-838, 2008

### **Lipman, Mark**

--Raju DL, Canatorvich M, Brisson M-L, Tchervenkov J, **Lipman ML**. Primary hyperoxaluria: Clinical course, diagnosis, and treatment after kidney failure. *American Journal of Kidney Disease*, 51: e1-e5, 2008

### **Lin, Rongtuan**

--Escors D, Lopes L, Lin R, **Hiscott J**, Akira S, Davis RJ, Collins MK. Targeting dendritic cell signaling to regulate the response to immunization. *Blood* 111:3050-3061, 2008

### **Miller, Mark**

--**Miller M**. Comment on: Hickson M et al. Use of probiotic *Lactobacillus* preparation to prevent diarrhoea associated with antibiotics. *Evidence-Based Medicine*, 13:46, 2008

### **Miller, Wilson H.**

--Blumenschein GR, Gatzemeier U, Jotte RM, Khuri FR, Le Treut J, **Miller WH Jr**, von Pawel J, GFPC (Groupe Francis Pneumo Cancerologie). Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II *Journal of Clinical Oncology*, 10:26:1879-85, 2008

-- Baldwin A, Dupéré-Richer, D, **Miller WH Jr.**, Padovani A, Pettersson F, Summers-Deluca L, Witcher M,. Retinoic acid modulates chromatin to potentiate tumor necrosis factor alpha signaling on the DIF2 promoter. *Nucleic Acids Research*, 2008, 36:435-443, 2008

--Hanna N, McNamara S, **Miller WH Jr**, Wang H, Topoisomerase IIbeta negatively modulates RARalpha function- a novel mechanism of resistant APL. *Mol Cell Biol*, 28:2066-77, 2008

--Colombo M, Mann KK, **Miller WH Jr**. Arsenic trioxide decreases AKT protein in a caspase-dependent manner, *Molecular Cancer Therapeutics*, 7:1680-1687, 2008

--Bodoky G, Garay C, Habboubi N, Haller DG, Koralewski PM, **Miller WH Jr.**, Olivatto LO, Rothenberg ML, Wong AO. Oxaliplatin plus Irinotecan Compared to Irinotecan Alone as Second-Line Treatment After Single-Agent Fluoropyrimidine Therapy for Metastatic Colorectal Carcinoma. *J Clin. Oncology*, 26(28):4544-50, 2008

--Chabot S, Chatterjee A, Colombo M, Mann KK, **Miller WH Jr**, Trottier C, Ward BJ. Retinoids inhibit measles virus in vitro via nuclear retinoid receptor signaling pathways. *Antiviral Research*, 80:45-53, 2008

--Choi C, Couture MC, Dupéré-Richer D, Hanna N, Lagodich M, **Miller WH Jr.**, Pettersson F. Retinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner. *J Biol Chem*, 8:283(32):21945-52, 2008

--Colombo M, Diaz Z, Kourelis M, Mann KK, Marcoux S, **Miller WH Jr**. A Novel Arsenical has Anti-tumor Activity toward As<sub>2</sub>O<sub>3</sub>-resistant and MRP1/ABCC1-overexpressing cell lines. *Leukemia*, (22) 1853-63, 2008

--Laurenzana A, **Miller WH Jr.**, Pettersson F. Role of PML/RARa in the pathogenesis of APL. *Drug Discovery Today: Disease Mechanisms*, 3:499-505, 2008

--**Miller WH Jr.** and Pettersson F. Epigenomic repression by APL oncoprotein. *Blood*, 111:2498, 2008

--McNamara, S and **Miller WH Jr.**, Expanding the use of retinoids in AML: Spotlight on bexarotene. *Clinical Cancer Research*, 14, 5311-5313, 2008

### **Monette, Johanne**

--Retornaz F, **Monette J**, Batist G, Monette M, Sourial N, Wan-Chow-Wah D, Puts N, Small D, Caplan S, Bergman H. Usefulness of Frailty Markers in the Assessment of Health and Functional Status in Older Cancer Patients Referred for Chemotherapy. *J Gerontol A Biol Sci Med Sci*, 63:518-522, 2008

--**Monette J**, Champoux N, Monette M, Fournier L, Wolfson C, Galbaud du Fort G, Sourial N, Le Cruguel J-P, Gore Brian. Effect of an interdisciplinary educational program on antipsychotic prescribing among nursing home residents with dementia. *Int J Geriatr Psychiatry*. 23:574-9, 2008

--Arcand M, **Monette J**, Monette M, Sourial N, Fournier L, Gore B, **Bergman H**. Educating nursing home staff about the progression of dementia and the comfort care option: impact on family satisfaction with end-of-life care. *JAMDA*, 10:50-5, 2008

--Tellier C, **Monette J**, **Gold S**, Montero-Odasso M, Le-Cruguel JP, Papadopoulos G. Fear of falling and orthostatic hypotension : a case series from a geriatric outpatient clinic. *Canadian Journal of Geriatrics*, 11:99-103, 2008

### **Oughton, Matthew**

--**Oughton MT**, Miller MA. Clinical and Epidemiological Aspects of Clostridium difficile. *Clin Microbiology Newsletter* 30:12:87-96, 2008

--**Oughton MT**, Dascal A. "Acute Infectious Diarrhea" chapter in: *Conn's Current Therapy*, 2008 edition, Elsevier, St. Louis, MO, pp12-19

### **Panasci, Lawrence**

--Amrein L, Hernandez TA, Ferrario C, Johnston J, Gibson SB, **Panasci L**, Aloyz R. Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. *Br J Haematol*, 143:5:698-706, 2008

### **Pantopoulos, Kostas**

--Wang J, Chen G, Lee, J, and **Pantopoulos K**. Iron-dependent degradation of IRP2 requires its C-terminal region and IRP structural integrity, *BMC Mol Biol*, 9:15, 2008

--Koliaraki V, Marinou M, Samiotaki M, Panayotou G, **Pantopoulos K**. and Mamalaki A Iron regulatory and bactericidal properties of recombinant hepcidin expressed in *Pichia pastoris*, *Biochimie*, 90:726-735, 2008

--Dycke C, Charbonnier P, **Pantopoulos K** and Moulis J-M. A role for lysosomes in human iron regulatory protein 2 turnover, *Int J Biochem Cell Biol*, 40:2826-2832, 2008

--Wang J, Chen G, Fillebeen C and **Pantopoulos K**. Insights on regulation and function of the iron regulatory protein 1 (IRP1), *Hemoglobin*, 32:109-115, 2008

--Zimmer M, Ebert B L, Neil C, Brenner K, Papaioannou I, Melas A, Tolliday N, Lamb J, **Pantopoulos K**, Golub T and Iliopoulos O. Small molecule inhibitors of HIF-2 $\alpha$  translation link its 5' -UTR iron-responsive element (IRE) to oxygen sensing, *Mol Cell*, 32:838-848, 2008

--**Pantopoulos K**. Function of the hemochromatosis protein HFE: Lessons from animal models, *World J Gastro*, 14:6893-6901, 2008

--Galaris D and **Pantopoulos K**. Oxidative stress and iron homeostasis: mechanistic and health aspects, *Crit Rev Clin Lab Sci*, 45:1-23, 2008

--Fillebeen C, Moulis J-M and **Pantopoulos K**. Post-transcriptional regulation of cellular iron homeostasis, *Iron Metabolism and Disease* (ed. Fuchs H), *Research Signpost*, 289-314, 2008

--Sebastiani G and **Pantopoulos K**. Non-HFE related iron storage disease. *International Hepatology Updates – Metabolic and Storage Liver Diseases* (ed. Arroyo, V), 13-32, 2008

### **Pepe, Carmela**

--Dajczman E, Kasymjanova G, Kreisman H, Swinton N, **Pepe C**, Small D. Should patient-rated performance status affect treatment decisions in advanced lung cancer? *Journal of Thoracic Oncology*, 3:49-53, 2008

### **Pollak, Michael**

--Zakikhani M, Dowling RJ, Sonenberg N, **Pollak MN**. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. *Cancer Prev Res (Phila Pa)*, 1:5:369-75, 2008

--Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, **Pollak M**, Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. *Cancer Res*, 68:24:10238-46, 2008

--Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, **Pollak M**. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. *Clin Cancer Res*. 14:24:8263-9, 2008 Epub 2008 Dec 10.

-- **Pollak M**. Insulin and insulin-like growth factor signalling in neoplasia. *Nat Rev Cancer*, 9:15-28, 2008. Review



-- So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, **Pollak M**. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. *Clin Cancer Res*. 14:21:6944-54, 2008

--**Pollak M**. Insulin, insulin-like growth factors and neoplasia. *Best Pract Res Clin Endocrinol Metab*, 22:4:625-38, 2008. Review

--Chitnis MM, Yuen JS, Protheroe AS, **Pollak M**, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. *Clin Cancer Res*, 14:20:6364-70, 2008. Review

--Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, **Pollak M**, Nielsen TO, Huntsman D, Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. *Breast Cancer Res*, 10:5:R86, 2008. Epub 2008 Oct 16.

-- Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, **Pollak M**, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelmann JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. *Ann Intern Med*, 149:7:461-71, W83-8, 2008

--Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, , Stampfer MJ, **Pollak M**. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. *Lancet Oncol*, 10:39-47, 2008. Epub 2008 Oct 3.

--Stolzenberg-Solomon RZ, Weinstein S, **Pollak M**, Tao Y, Taylor PR, Virtamo J, Albanes D. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. *Am J Epidemiol*. 168:9:1047-55, 2008. Epub 2008 Sep 18.

--Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, **Pollak M**. Insulin receptor expression by human prostate cancers. *Prostate*, 69:33-40, 2008

--Vitamin D pathway polymorphisms in relation to mammographic breast density. Diorio C, Sinotte M, Brisson J, Bérubé S, **Pollak M**. *Cancer Epidemiol Biomarkers Prev*, 17:2505-8, 2008

--Page JH, Ma J, **Pollak M**, Manson JE, Hankinson SE. 20: Plasma insulinlike growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. *Clin Chem*, 54:1682-8, 2008. Epub 2008 Aug 14.

--**Pollak M**. Targeting insulin and insulin-like growth factor signalling in oncology. *Curr Opin Pharmacol*. 8:4:384-92, 2008. Epub 2008 Aug 20. Review.

--Max JB, Limburg PJ, Ogunseitan A, Stolzenberg-Solomon RZ, Vierkant RA, **Pollak MJ**, Sellers TA, Virtamo J, Cerhan JR, Albanes D. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 ratio: no association

with incident colorectal cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. *Cancer Epidemiol Biomarkers Prev*, 17:1832-4, 2008

--Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, **Pollak M**, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. *Prostate*, 68:13:1477-86, 2008

--Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorransoro M, Dossus L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, **Pollak M**, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS; IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). *Breast and Prostate Cancer Cohort Consortium, PLoS ONE*. 3:e2578, 2008

--Kaplan RC, McGinn AP, **Pollak MN**, Kuller L, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. *Am Heart J*, 155:1006-12, 2008 Epub 2008 Mar 5.

--Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, **Pollak M**. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. *Bruchim I. Gynecol Oncol*. 110(2):246-50, 2008. Epub 2008 May 21.

--Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, **Pollak M**, Jagannath S, Richardson P, Gualberto A. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. *J Clin Oncol*, 26:19:3196-203, 2008. Epub 2008 May 12.

--Diorio C, Brisson J, Bérubé S, **Pollak M**. Intact and total insulin-like growth factor-binding protein-3 (IGFBP-3) levels in relation to breast cancer risk factors: a cross-sectional study. *Breast Cancer Res*, 10:3:R42, 2008. Epub 2008 May 9.

--Algire C, Zakikhani M, Blouin MJ, Shuai JH, **Pollak M**. Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. *Endocr Relat Cancer*, 15:3:833-9, 2008. Epub 2008 May 9.

--Van Oijen M, Okereke OI, Kang JH, **Pollak MN**, Hu FB, Hankinson SE, Grodstein F. Fasting insulin levels and cognitive decline in older women without diabetes. *Neuroepidemiology*, 30:3:174-9, 2008. Epub 2008 Apr 17.

--Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, **Pollak MN**, Anderson G, Howard BV, Strickler HD. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. *Cancer Epidemiol Biomarkers Prev*, 17:4:921-9, 2008

--Diorio C, Brisson J, Bérubé S, **Pollak M**. Genetic polymorphisms involved in insulin-like growth factor (IGF) pathway in relation to mammographic breast density and IGF levels. *Cancer Epidemiol Biomarkers Prev*, 17:880-8, 2008

--Kasper JS, Liu Y, **Pollak MN**, Rifai N, Giovannucci E. Hormonal profile of diabetic men and the potential link to prostate cancer. *Cancer Causes Control*, 19:7:703-10, 2008. Epub 2008 Mar 14.

--Kaplan RC, McGinn AP, **Pollak MN**, Kuller L, Strickler HD, Rohan TE, Xue X, Kritchevsky SB, Newman AB, Psaty BM. Total insulinlike growth factor 1 and insulinlike growth factor binding protein levels, functional status, and mortality in older adults. *J Am Geriatr Soc*, 56:652-60, 2008. Epub 2008 Feb 27.

--Okereke OI, **Pollak MN**, Hu FB, Hankinson SE, Selkoe DJ, Grodstein F. Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. *Psychoneuroendocrinology*. 33:4:455-61, 2008. Epub 2008 Feb 7.

--Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, **Pollak MD**, Whittemore AS, Wu AH, Gallagher RP. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. *Cancer Epidemiol Biomarkers Prev*, 17:252-4, 2008

Ponka, Prem

--Rathore KI, Kerr BJ, Redensek A, López-Vales R, Jeong SY, **Ponka P**, David S. Ceruloplasmin protects injured spinal cord from iron-mediated oxidative damage. *J Neurosci*, 28:12736-12747, 2008

--Simunek T, Sterba M, Popelova O, Kaiserova H, Adamcova M, Hroch M, **Ponka P**, Gersl V. Anthracycline toxicity to cardiomyocytes or cancer cells is differently affected by iron chelation with salicylaldehyde isonicotinoyl hydrazone. *Br J Pharmacol*, 155:138-148, 2008.

--Soe-Lin S, Sheftel AD, Wasyluk B, **Ponka P**. Nramp1 equips macrophages for efficient iron recycling. *Exp Hematol*, 36:929-937, 2008

--Whitnall M, Suryo Rahmanto Y, Sutak R, Xu X, Becker EM, Mikhael M, **Ponka P\*** (\*Corresponding author), Richardson DR. The MCK mouse heart model of Friedreich's Ataxia: Marked alterations in iron-regulated proteins and iron chelation limits cardiac hypertrophy. *Proc Natl Acad Sci USA*, 105:9757-9762, 2008

--Zhang A-S, Canonne-Hergaux F, Gruenheid S, Gros P, **Ponka P**. The use of Nramp-2-transfected Chinese hamster ovary cells and reticulocytes from mk/mk mice to study iron transport mechanisms. *Exp Hematol*, 36:1227-1235, 2008

**Richard, Stephane**

--**Richard S**, Vogel G, Huot ME, Guo T, Muller W and Lukong KE. Sam68 Haploinsufficiency Delays Onset of Mammary Tumorigenesis and Metastasis. *Oncogene*, 27:548-56, 2008

--Lukong KE and **Richard S**. Breast tumor kinase BRK requires kinesin-2 subunit KAP3A in modulation of cell migration. *Cellular Signaling* 20:432-442, 2008

--Dery U, Coulomber Y, Rodrigue A, Stasiak A, **Richard S** and Masson JY. A glycine-arginine motif in control of the human MRE11 DNA repair protein. *Mol. Cell. Biol.* 28:3058-69, 2008

--Lukong KE and **Richard S**. Motor coordination defects in mice deficient for the Sam68 RNA binding protein. *Behaviour Brain Research* 189:357-63, 2008

--Lukong KE, Chang KW, Khandjian EW and **Richard S**. RNA binding proteins in human disease. *Trends in Genetics* 24:416-25, 2008

### **Richards, J. Brent**

--**Richards JB**, Yuan X, Geller F, Waterworth D, Bataille V, Glass D, Song K, Waeber G, Vollenweider P, Aben KK, Kiemeny LA, Walters B, Soranzo N, Thorsteindottir U, Kong A, Rafnar T, Deloukas P, Sulem P, Stefansson H, Stefansson K, Spector TD, Mooser V. Genome-Wide Association Study Reveals a Novel Locus for Male Pattern Baldness. *Nature Genetics*, 40:1281-4, 2008

--**Richards JB**, Rivadeneira F, Inouye M, Pastinen TM, Soranzo N, Wilson SG, Falchi M, Gwilliam R, Ahmadi KR, Arp P, Whittaker P, Andrew T, Jhamai M, Kumanduri V, Moorhouse M, van Meurs JB, Hofman A, Pols HAP, Hart D, Zhai G, Valdes AM, Kato BS, Mullin BH, Zhang F, Deloukas P, Uitterlinden AG, Spector TD. Genome-Wide Association Study for Bone Mineral Density Reveals Genetic Variants Associated with Osteoporosis and Osteoporotic Fractures. *The Lancet*, 371 (9623):1505-12, 2008.

--Panicker V, Wilson SG, Spector TD, Brown SJ, Falchi M, **Richards JB**, Surdelescu G, Lim EM, Fletcher S and Walsh JP. Genetic loci linked to pituitary-thyroid axis setpoints: A genome-wide scan of a large twin cohort. *Journal of Clinical Endocrinology & Metabolism*, 93: 3519-23, 2008  
Cherkas L, Hunkin J, Kato B, **Richards JB**, Gardner JP, Aviv A, Spector TD. Physical Activity and Leukocyte Telomere Length in Women. *Arch. Int. Med.* , 168:154-158, 2008

--Zhai G, Hart D, Valdes AM, Kato B, **Richards JB**, Hakim A , Spector TD. Natural History and Risk Factors of Bone Loss in Postmenopausal Caucasian Women: A 15-Year Follow-Up Population-Based Study. *Osteoporos Int.*, 19:1211-7, 2008

--**Richards JB** , Valdes AM, Gardner JP, Kato BS, Siva A, Kimura M, Lu X, Brown MJ, Aviv, Spector TD. Homocysteine Levels and Leukocyte Telomere Length. *Atherosclerosis*, 200:271-77, 2008

--Skidmore PMI, Cassidy A, Swaminathan R, **Richards JB**, Spector TD, Macgregor AJ. Relation of birth weight, BMI and change in size from birth to adulthood to insulin resistance in a female twin cohort. *J Clin Endocrinol Metab*,93:516-20, 2008

### **Rosenblatt, David S.**

--Coelho D, Suormala T, Stucki M, Lerner-Ellis J, **Rosenblatt DS**, Newbold RF, Baumgartner MR, Fowler B. Gene identification and mutations of the cblD defect of vitamin B12 metabolism: one gene three phenotypes. *N Engl J Med* 358: 1454-1464, 2008

--Marble M, Copeland S, Khanfar H, and **Rosenblatt DS**. Neonatal vitamin B12 deficiency secondary to maternal subclinical pernicious anemia: Identification by expanded newborn screening. *J Pediatr* 152:731-733, 2008

--Yamani L, Gibbs BF, Gilfix BG, Watkins D, Hosack A, **Rosenblatt DS**. Transcobalamin in cultured fibroblasts from patients with inborn errors of vitamin B12 metabolism. *Mol Genet Metab* 95: 104-106, 2008

--Prasad C, **Rosenblatt DS**, Corley K, Cairney AEL, Rupa CA. Transcobalamin (TC) deficiency-potential cause of bone marrow failure in childhood. *J Inher Metab Dis*, 31: 775, 2008

### **Therrien, Judith**

-- Khairy P, Harris L, Landzberg MJ, Viswanathan S, Barlow AM, Gatzoulis MA, Fernancer SM, Beauchesne L, **Therrien J**, Chetaille P, Gordon E, Vonder Muhll I, Ceccin F. Implantable cardioverter-defibrillators in tetralogy of Fallot. *Circulation*, 117:363-370, **2008**

--**Therrien J**, Provost Y, Harrison J, Connelly M, Daemmerer H, Webb GD. Effect of Angiotensin Receptor Blockade on Systemic Right Ventricular Function and Size: a Multicenter, Double Blind, Randomized, Placebo-Controlled Clinical Trial. *International Journal of Cardiology*, 129:187-192, 2008

--Thanassoulis G, Yip J, Jamorski M, Webb G, Siu S, **Therrien J**. Aortic Root Dilatation and Progression in Patients with Bicuspid Aortic Valve. *Nature Clinical Practice cardiovascular Medicine*, 5:821-8, 2008

--Tzemos N, **Therrien J**, Yip J, Thanassoulis G, Tremblay S, Jamorski M, Webb G, Siu SC. Outcomes in Adult with Congenital Bicuspid Aortic Valves. *Jama*, 300:1317-25, 2008

### **Schiffirin, Ernesto**

--Levy BI, **Schiffirin EL**, Mourad JJ, Agostini D, Vicaut E, Safar ME, Struijker-Boudier HA. Impaired tissue perfusion: a pathology common to hypertension, obesity, and diabetes mellitus. *Circulation*, 118:968-76, 2008

--Dhaun N, Goddard J, Kohan DE, Pollock DM, **Schiffirin EL**, Webb DJ. Role of endothelin-1 in clinical hypertension: 20 years on. *Hypertension*, 52(3):452-9, 2008

--Ebrahimian T, Sairam MR, **Schiffirin EL**, Touyz RM. Cardiac hypertrophy is associated with altered thioredoxin and ASK-1 signaling in a mouse model of menopause. *Am J Physiol Heart Circ Physiol*, 295(4):H1481-8, 2008

- Marchesi C, Paradis P, **Schiffrin EL**. Role of the renin-angiotensin system in vascular inflammation. *Trends Pharmacol Sci*, 29:367-74, 2008
- Tabet F, **Schiffrin EL**, Callera GE, He Y, Yao G, Ostman A, Kappert K, Tonks NK, Touyz RM. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. *Circ Res*, 103(2):149-58, 2008
- Khan NA, Hemmelgarn B, Herman RJ, Rabkin SW, McAlister FA, Bell CM, Touyz RM, Padwal R, Leiter LA, Mahon JL, Hill MD, Larochelle P, Feldman RD, **Schiffrin EL**, Campbell NR, Arnold MO, Moe G, Campbell TS, Milot A, Stone JA, Jones C, Ogilvie RI, Hamet P, Fodor G, Carruthers G, Burns KD, Ruzicka M, dechamplain J, Pylypchuk G, Petrella R, Boulanger JM, Trudeau L, Hegele RA, Woo V, McFarlane P, Vallée M, Howlett J, Katzmarzyk P, Tobe S, Lewanczuk RZ; Canadian Hypertension Education Program. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. *Can J Cardiol*, 24:465-75, 2008
- Padwal RJ, Hemmelgarn BR, Khan NA, Grover S, McAlister FA, McKay DW, Wilson T, Penner B, Burgess E, Bolli P, Hill MD, Mahon J, Myers MG, Abbott C, **Schiffrin EL**, Honos G, Mann K, Tremblay G, Milot A, Cloutier L, Chockalingam A, Rabkin SW, Dawes MD, Touyz RM, Bell C, Burns KD, Ruzicka M, Campbell NR, Lebel M, Tobe SW; Canadian Hypertension Education Program. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. *Can J Cardiol*, 24:455-63, 2008
- Schiffrin EL**. The flame that lights the fire: oxidative stress, inflammation, and renal damage in angiotensin II-induced hypertension. *Hypertension*, 52(2):205-6, 2008
- Leibovitz E, **Schiffrin EL**. New treatments in hypertension: direct renin inhibitors. *Harefuah*, 147:218-23, 278, 2008
- Viel EC, Benkirane K, Javeshghani D, Touyz RM, **Schiffrin EL**. Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats. *Am J Physiol Heart Circ Physiol*, 295:H281-8, 2008
- Amiri F, Paradis P, Reudelhuber TL, **Schiffrin EL**. Vascular inflammation in absence of blood pressure elevation in transgenic murine model overexpressing endothelin-1 in endothelial cells. *J Hypertens*, 26:1102-9, 2008
- Lemarié CA, Paradis P, **Schiffrin EL**. New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone. *J Mol Med*, 86:673-8, 2008
- Touyz RM, **Schiffrin EL**. Reactive oxygen species and hypertension: a complex association. *Antioxid Redox Signal*, 10:1041-4, 2008
- Schiffrin EL**. New twist to the role of the renin-angiotensin system in heart failure: aldosterone upregulates renin-angiotensin system components in the brain. *Hypertension*. 51:622-3, 2008

--Savoia C, Touyz RM, Amiri F, **Schiffrin EL**. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. *Hypertension*, 51:432-9, 2008

--Pu Q, Brassard P, Javeshghani DM, Iglarz M, Webb RL, Amiri F, **Schiffrin EL**. Effects of combined AT1 receptor antagonist/NEP inhibitor on vascular remodeling and cardiac fibrosis in SHRSP. *J Hypertens*, 26:322-33, 2008

--**Schiffrin EL**. Oxidative stress, nitric oxide synthase, and superoxide dismutase: a matter of imbalance underlies endothelial dysfunction in the human coronary circulation. *Hypertension*, 51:31-2, 2008

--Touyz RM, **Schiffrin EL**. Hypertension and oxidative stress In: Atherosclerosis and oxidant stress: A new perspective, Holtzman JL Editor, Springer Science, New York, NY, Chapter 4, pp 51-78, 2008

--Savoia C, **Schiffrin EL**. Biomarkers in hypertension update: current and future roles. In: The Year in Hypertension 2008. R. Townsend Editor, Clinical Publishing / Atlas Medical Publishing Ltd, Oxford, UK, 2008, pp 19-38, 2008

### **Schipper, Hyman M**

--Henri-Bhargava A, Melmed C, Glikstein R, **Schipper HM**. Neurological impairment due to vitamin E and copper deficiencies in celiac disease. *Neurology*, 71:860-861, 2008

**Schipper HM**, Kwok CS, Rosendahl SM, Bandilla D, Maes O, Melmed C, Rabinovitch D, Burns DH. Spectroscopy of human plasma for diagnosis of idiopathic Parkinson disease. *Biomarkers Med*, 2:229-238, 2008

--Bui E, Ehrensperger E, Sahlas DJ, Murray BJ, Bergeron C, Glikstein RS, Aviv R, **Schipper HM**. Inflammatory cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. *Can J Neurol Sci*, 35:625-629, 2008

--Feldman HH, Robillard A, Garcia A, Chow T, Borrie M, **Schipper HM**, Jacova C, Blair M, Kertesz A. The diagnosis of dementia. *Can Med Assoc J*, 178:825-836, 2008

--**Schipper HM**. Sex hormones and the nervous system. In Aminoff MJ (ed): Neurology and General Medicine, 4th ed, Elsevier: Amsterdam, 409-426, 2008

### **Small, David**

--Eisen T, Thatcher N, Leyvraz S, Miller WH JR, Couture F, Lorigan P, Lüthi F, **Small D**, Tanovic A, O'Brien M. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. *Lung Cancer* 2008[Epub ahead of print]

### **Szilagyi Andrew**

---Heilpern D, **Szilagyi A**. Manipulation of intestinal microbial flora for therapeutic benefit in inflammatory bowel diseases: Review of clinical trials of probiotics, prebiotics and synbiotics.

Rev Recent Clin Trials 3; 167-184, 2008.

---**Szilagyi A**. Risk modification of inflammatory bowel diseases by vitamin D, calcium lactase/lactose interactions: Arguments based on relationships between IBD and colorectal cancer. In Research trends in nutrition for the middle aged and elderly. JP Urster ed. Nova Science Publishers Inc. New York, 7-51, 2008

### **Tagalakis, Vicky**

--**Tagalakis V**, Tamim H. Validating a method that deals with missing drug information in the Saskatchewan Prescription Drug Plan database. *Pharmacoepidemiology and Drug Safety*, 17:1-7, 2008

### **Tischkowitz, Marc**

--**Tischkowitz M**, Sabbaghian N, Ray AM, Lange EM, Foulkes WD, Cooney KA. Analysis of the Gene Coding for the BRCA2-Interacting Protein PALB2 in Hereditary Prostate Cancer. *The prostate*, 68:6:675-8, 2008

--**Tischkowitz M**, Hamel N, Carvalho MA, Birrane G, Soni A, van Beers EH, Joosse SA, **Wong N**, Novak D, Quenneville LA, Grist S, kConFab, Nederlof PM, Goldgar DE, Tavtigian SV, Monteiro ANA, Ladias JAA, Foulkes WD. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket – a multi-modal approach. *Eur J Hum Genet*, 16:7:820-32, 2008

--Hamel N, **Tischkowitz M**, Foulkes WD. [A role for PALB2/FANCN in breast cancer predisposition?] *Med Sci (Paris)*, 24:2:120-1, 2008

--**Tischkowitz MD**, Yilmaz A, Chen LQ, Karyadi DM, Novak D, Kirchhoff T, Hamel N, Tavtigian SV, Kolb S, Bismar TA, Aloyz R, Nelson PS, Hood L, Narod SA, White KA, Ostrander EA, Isaacs WB, Offit K, Cooney KA, Stanford JL, Foulkes WD. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer. *Cancer Lett*, 270:1:173-1780, 2008

--Campeau PM, Foulkes WD, **Tischkowitz MD**. Hereditary breast cancer: new genetic developments, new therapeutic avenues. *Hum Genet*, 124:1:31-42, 2008

--Novak DJ, Sabbaghian N, Maillet P, Chappuis PO, Foulkes WD, **Tischkowitz M**. Analysis of the genes coding for the BRCA1-interacting proteins, RAP80 and Abraxas (CCDC98), in high-risk, non-BRCA1/2, multiethnic breast cancer cases. *Breast Cancer Res Treat*. 2008 Aug 10. [Epub ahead of print]

-- **Tischkowitz M**, Easton DF, Ball J, Hodgson SV, Mathew CG. Cancer Incidence in Relatives of British Fanconi Anaemia Patients. *BMC Cancer*. 8:1:257, 2008

-- Georgitsi M, Heliövaara E, Paschke R, Kumar AV, **Tischkowitz M**, Vierimaa O, Salmela P, Sane T, De Menis E, Cannavò S, Gündogdu S, Lucassen A, Izatt L, Aylwin S, Bano G, Hodgson S, Koch CA, Karhu A, Aaltonen LA. Large Genomic Deletions of Aryl Hydrocarbon Receptor Interacting



Protein (AIP) Gene in Pituitary Adenoma Predisposition. *J Clin Endocrinol Metab*, 93:10:4146-51, 2008

**Wolkove, Norman**

--**Wolkove N**, Baltzan, M, Kamel H, Dabrussin R, Palayew M. Long-term compliance with continuous positive airway pressure in patients with obstructive sleep apnea. *Can Respir*, 15:7:365-369, 2008

--Baltzan MA, Elkholi O, **Wolkove N**. Evidence of interrelated side effects with reduced compliance in patients treated with nasal continuous positive airway pressure. *Sleep Med*, 10:2:198-205, 2009; Epub Mar 7, 2008

**Zaharatos, Gerasimos**

--Hofmann A, **Zaharatos G**, Miller M. Case report and review of the literature: *Toxoplasma gondii* encephalitis in a 40-year-old woman with common variable immunodeficiency and a new diagnosis of large granular lymphocytic leukemia. *CJIDMM*, 19:309-10, 2008

261 publications